Vladimir Zah
Vladimir Zah
ZRx Outcomes Research Inc.
Підтверджена електронна адреса в outcomesresearch.ca - Домашня сторінка
Role of health technology assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries
K Kolasa, Z Kalo, V Zah, T Dolezal
Expert review of pharmacoeconomics & outcomes research 12 (3), 283-287, 2012
Health technology assessment for molecular diagnostics: practices, challenges, and recommendations from the medical devices and diagnostics special interest group
S Garfield, J Polisena, DS Spinner, A Postulka, CY Lu, SK Tiwana, ...
Value in Health 19 (5), 577-587, 2016
Analysis of buprenorphine/naloxone dosing impact on treatment duration, resource use and costs in the treatment of opioid-dependent adults: a retrospective study of US public …
A Khemiri, E Kharitonova, V Zah, J Ruby, M Toumi
Postgraduate medicine 126 (5), 113-120, 2014
Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence
E Clay, A Khemiri, V Zah, S Aballéa, J Ruby, CV Asche
Journal of Medical Economics 17 (9), 626-636, 2014
Budgetary impact of the utilization of buprenorphine/naloxone sublingual film and tablet for Medicaid in the United States
CV Asche, E Clay, E Kharitonova, V Zah, J Ruby, S Aballéa
Journal of Medical Economics 18 (8), 600-611, 2015
Multicriteria decision analysis to support health technology assessment agencies: benefits, limitations, and the way forward
R Baltussen, K Marsh, P Thokala, V Diaby, H Castro, I Cleemput, M Garau, ...
Value in Health 22 (11), 1283-1288, 2019
How can multi criteria decision analysis support value assessment of pharmaceuticals?-Findings from a systematic literature review
K Kolasa, V Zah, M Kowalczyk
Expert Review of Pharmacoeconomics & Outcomes Research 18 (4), 379-391, 2018
The use of non-economic criteria in pricing and reimbursement decisions in Central and Eastern Europe: issues, trends and recommendations
K Kolasa, Z Kalo, V Zah
Expert Review of Pharmacoeconomics & Outcomes Research 16 (4), 483-488, 2016
Challenges in assessing and appraising rare disease diagnostics & treatments
M Toumi, C Pashos, D Korchagina, K Redekop, T Morel, C Blanchette
International Society for Pharmacoeconomics and Outcomes Research Rare …, 2015
Budgetary impact of adding roflumilast to managed care formulary in the treatment of chronic obstructive pulmonary disease
S Sun, V Zah, S Blum
Med. Decis. Making, E124-E125, 2012
Health Technology Assessment in Serbia
D Atanasijevic, V Zah
International Journal of Technology Assessment in Health Care 33 (3), 384-389, 2017
Eliciting Payers Preferences In Central And Eastern Europe: Results Of Mcda Case Study
O Piniazhko, O Zalis' ka, V Zah
Value in Health 19 (7), A367, 2016
Revealed preferences towards the appraisal of orphan drugs in Poland-multi criteria decision analysis
K Kolasa, KM Zwolinski, V Zah, Z Kaló, T Lewandowski
Orphanet journal of rare diseases 13 (1), 67, 2018
Budget Impact of Introducing Linagliptin into Bosnia and Herzegovina Health Insurance Drug Reimbursement List in 2016-2018
T Catic, L Lekic, V Zah, V Tabakovic
Materia Socio-Medica 29 (3), 176, 2017
economic and health implications from earlier detection of HIV infection in the United Kingdom
V Zah, M Toumi
Hiv/aids (Auckland, NZ) 8, 67, 2016
Zrx Mcdm: a fully flexible tool to support the local adaptation of multiple-criteria decision criteria in health care
V Zah, S Thompson, M Berjan, R Goeree
Value in Health 18 (7), A703, 2015
Analysis of ‘Revolving Door'Patients in Opioid Dependent Patients: the Impact of Treatment Discontinuation on Relapse Rates and Health Care Costs in us Public Health Insurance …
E Clay, V Zah, E Kharitonova, J Ruby, S Aballéa, A Khemiri
Value in Health 17 (7), A456, 2014
Patient persistence with buprenorphine/naloxone film and tablet formulations in the treatment of opioid dependence in the United States: results from a 2010–2012 privately …
E Clay, A Khemiri, J Ruby, S Aballea, V Zah
Canadian Journal of Addiction 5 (2), 23, 2014
A studies-based private insurance budget impact analysis of buprenorphine/naloxone film and tablet formulations
E Clay, A Khemiri, J Ruby, S Aballea, V Zah
Value in Health 17 (3), A213, 2014
Medicaid population budget impact analysis of buprenorphine/naloxone film and tablet formulation
E Clay, E Kharitonova, J Ruby, S Aballea, V Zah
Value in Health 17 (3), A212, 2014
У даний момент система не може виконати операцію. Спробуйте пізніше.
Статті 1–20